Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Temsirolimus Shows Promise for Ovarian, Peritoneal Cancers: Presented at SGO By Fred Gebhart SAN FRANCISCO -- March 18, 2010 -- Temsirolimus may have modest cytostatic activity in patients with prior chemotherapy, according to a study presented here at the Society of Gynecologic Oncologists (SGO) 41st Annual Meeting on Women’s Cancer. Mammalian target of rapamycin (mTOR) is a promising target in various cancers including epithelial, ovarian, and primary peritoneal malignancies. “Inactivation of mTOR inhibitors can lead to inappropriate activation of cellular growth pathways, promoting carcinogenesis,” said Kian Behbakht, MD, University of Colorado Denver, Aurora, Colorado, on March 15. The Gynecologic Oncology Group trial 170I examined a commercially available mTOR inhibitor, temsirolimus, in epithelial ovarian and primary peritoneal malignancies. Women with measurable, persistent, or recurrent epithelial ovarian or primary peritoneal cancers who have received multiple chemotherapy regimens have few treatment options, said Dr. Behbakht. Researchers enrolled 60 women with up to 3 prior chemotherapy regimens in an open-label, single-arm, phase 2 study to evaluate response and progression-free survival at 6 months. Women in the trial received receive intravenous temsirolimus 25 mg on days 1, 8, 15, and 21 of a 28-day cycle. Treatment was continued until progression or withdrawal because of toxicity. The study also evaluated any effect from temsirolimus on circulating tumour cells (CTCs). Patients in the study had archival tissue samples and pretreatment blood samples available. Additional blood samples were taken before each of the first 3 cycles to assess any CTC changes. Of the 54 evaluable patients, 24.1% were progression free at >=6 months, 9.3% had a partial response, and 40.7% had stable disease, for a combined response rate of 73.8%. The median progression-free survival was 3.19 months, and the median overall survival was 11.6 months. The longest progression-free survival in the trial was 21 months, Dr. Behbakht noted. “Toxicities were as expected for this class of agent,” he added. Common severe adverse events (grade 3/4) included metabolic toxicities, nausea, and other gastrointestinal events, pain, constitutional events, pulmonary events, anaemia, and infection. Detectable CTCs were associated with poorer survival, with an odds ratio of 4.16 favouring progression in patients with CTCs. High expression of the M30 gene was associated with a longer progression-free survival than low M30 gene expression (9.7 vs 2.2 months). Dr. Behbakht noted that the M30 association remains exploratory because it was observed in relatively few patients. The researchers concluded that temsirolimus may have modest cytostatic activity in patients with prior chemotherapy and should be investigated further. Dr. Behbakht suggested that the agent might be combined with bevacizumab for increased activity and is already being studied in combination with paclitaxel. He noted that isolation, enumeration, and characterisation of CTCs from patients should also be investigated in further trials. [Presentation title: Phase II Trial of the mTOR Inhibitor Temsirolimus and Evaluation of Circulating Tumor Cells in Persistent or Recurrent Epithelial Ovarian and Primary Peritoneal Malignancies: A Gynecologic Oncology Group Study. Abstract 7] E-mail this page to a friend or colleague! To print, use this version